EUVIMEDEUVIMED entdecken
Crossref

Are Higher-Order Carbapenems Effective Therapy for Patients with Ertapenem-Resistant Enterobacterales Invasive Infections?

Anne S Peters iD, Lorena Diaz iD, José R W Martínez iD, Pamela Rojas, María L Rioseco, Lina Rivas iD, Patricia Garcia, William R Miller iD, Pranita D Tamma iD, José M Munita iD

Clinical Infectious Diseases · 03.11.2026

DOI: 10.1093/cid/ciag696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 03.11.2026. Verfasst von Anne S Peters und 9 weiteren Autor:innen. Beteiligte Einrichtung: Genomics & Resistant Microbes (GeRM), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarroll….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The IDSA guidance suggests treating Enterobacterales resistant to ertapenem but susceptible to imipenem or meropenem with a susceptible carbapenem in the absence of carbapenemase production; however, clinical outcomes data are limited.

Methods

We conducted a multicenter prospective cohort study of hospitalized patients with invasive ceftriaxone-resistant Enterobacterales infections, comparing 30-day mortality between ertapenem-susceptible (ETP-S) and ertapenem-resistant (ETP-R) isolates. ETP-S isolates with an ESBL/AmpC phenotype served as the comparator because carbapenems are reliably active against these organisms. Carbapenem susceptibility was confirmed by broth microdilution. Inclusion criteria included: (1) susceptibility to imipenem or meropenem, (2) absence of carbapenemase genes, and (3) >72 hours of definitive therapy with imipenem or meropenem. Inverse probability weighting (IPW) adjusted for baseline differences, and logistic regression estimated odds ratios with 95% confidence intervals.

Results

Among 374 patients, 238 (64%) were infected with ETP-S and 136 (36%) ETP-R isolates. Baseline characteristics were balanced after IPW. ETP-R infection was associated with higher 30-day mortality (OR 2.24, 95% CI 1.26-3.98, p=0.006). Similarly, 14-day and in-hospital mortality were significantly higher among patients with ETP-R infections. The highest mortality was observed among patients with isolates resistant to two carbapenems (e.g., ertapenem and meropenem). Genomic analyses demonstrated enrichment of porin alterations and more non-carbapenemase β-lactamase genes (e.g., blaCTX-M, blaOXA-10) in ETP-R isolates.

Conclusion

Among patients with Enterobacterales bacteremia treated with imipenem or meropenem, ETP-R isolates were associated with higher mortality than ETP-S isolates, challenging current guidance. This likely reflects combined porin loss and increased β-lactamase activity, potentially resulting in partial hydrolysis of higher-order carbapenems despite in vitro susceptibility.

Schlagwörter

Stichwörter der Autor:innen

Escherichia coliKlebsiella pneumoniaeCREESBLsantimicrobial resistance

Autor:innen und Institutionen

  • Genomics & Resistant Microbes (GeRM), Instituto de Ciencias e Innovación en Medicina, Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Chile.
  • Multidisciplinary Initiative for Collaborative Research On Bacterial Resistance, Santiago, Chile.
  • Surveillance, Epidemiology, and New Technologies for Infectious Emerging Threats (SENTINET), Santiago, Chile.
  • Hospital Padre Hurtado, Santiago, Chile.
  • Hospital Puerto Montt, Puerto Montt, Chile.
  • Departamento de Laboratorios Clínicos, Escuela de Medicina, Universidad Católica de Chile, Santiago, Chile.

ORCID-Profile: Anne S Peters, Lorena Diaz, José R W Martínez, Lina Rivas, William R Miller, Pranita D Tamma, José M Munita

Zitieren

APA

Peters, A. S., Diaz, L., Martínez, J. R. W., Rojas, P., Rioseco, M. L., Rivas, L., Garcia, P., Miller, W. R., Tamma, P. D., & Munita, J. M. (2026). Are Higher-Order Carbapenems Effective Therapy for Patients with Ertapenem-Resistant Enterobacterales Invasive Infections?. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag696

Vancouver

Peters AS, Diaz L, Martínez JRW, Rojas P, Rioseco ML, Rivas L, et al. Are Higher-Order Carbapenems Effective Therapy for Patients with Ertapenem-Resistant Enterobacterales Invasive Infections?. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag696

BibTeX
@article{Peters2026,
  author = {Peters, Anne S and Diaz, Lorena and Martínez, José R W and Rojas, Pamela and Rioseco, María L and Rivas, Lina and Garcia, Patricia and Miller, William R and Tamma, Pranita D and Munita, José M},
  title = {Are Higher-Order Carbapenems Effective Therapy for Patients with Ertapenem-Resistant Enterobacterales Invasive Infections?},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciag696}
}
Kostenlos starten →